Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1721

Adult Primary Central Nervous System Vasculitis Treatment and Course: A Long-term Follow-up Study

9:00AM-11:00AM: Abstract Number: 1701

Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road

9:00AM-11:00AM: Abstract Number: 1695

Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases

9:00AM-11:00AM: Abstract Number: 1708

Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease

9:00AM-11:00AM: Abstract Number: 1693

Biological Therapy in Neurobehçet: Multicenter Study of 31 Patients

9:00AM-11:00AM: Abstract Number: 1714

Can We Predict Early Relapses in Adult IgA Vasculitis?

9:00AM-11:00AM: Abstract Number: 1710

Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1700

Clinical Characteristics and the Level Disease Activity of Behcet´s Disease in China: A Study Based on Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1719

Clinical Phenotypes in Relapsing Polychondritis in a Prospective Cohort

9:00AM-11:00AM: Abstract Number: 1705

Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?

9:00AM-11:00AM: Abstract Number: 1698

Development of Machine Learning Models (Artificial Neural Networks) for Prediction of Vision Threatening Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1699

Disease Course of Behçet’s Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation

9:00AM-11:00AM: Abstract Number: 1711

Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study

9:00AM-11:00AM: Abstract Number: 1687

Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis

9:00AM-11:00AM: Abstract Number: 1713

Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase

9:00AM-11:00AM: Abstract Number: 1697

Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study

9:00AM-11:00AM: Abstract Number: 1704

Efficacy of Leflunomide for Treatment of Vasculitis

9:00AM-11:00AM: Abstract Number: 1691

Efficacy of TNF α Inhibitors for Refractory Vascular Behcet’s Disease: A Multicenter Observational Study of 27 Patients

9:00AM-11:00AM: Abstract Number: 1718

Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017

9:00AM-11:00AM: Abstract Number: 1688

Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial

9:00AM-11:00AM: Abstract Number: 1712

Head and Neck Involvement of IgA Vasculitis: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1706

HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1717

Identifying Patterns of Histopathologic Presentation in CNS Vasculitis

9:00AM-11:00AM: Abstract Number: 1707

IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors

9:00AM-11:00AM: Abstract Number: 1703

Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 1685

Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014

9:00AM-11:00AM: Abstract Number: 1696

Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?

9:00AM-11:00AM: Abstract Number: 1709

Juvenile-Onset IgG4-Related Disease: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1692

Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1722

Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy

9:00AM-11:00AM: Abstract Number: 1723

Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients

9:00AM-11:00AM: Abstract Number: 1689

Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa

9:00AM-11:00AM: Abstract Number: 1720

Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome

9:00AM-11:00AM: Abstract Number: 1694

Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1716

Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study

9:00AM-11:00AM: Abstract Number: 1715

Predictors of Gastrointestinal and Renal Involvement in Adult IgA Vasculitis

9:00AM-11:00AM: Abstract Number: 1686

Risk of Vasculitis Associated with Inflammatory Bowel Diseases: Evidence for a Role of TNF-α Blockers

9:00AM-11:00AM: Abstract Number: 1702

Target Organ Associations in Polyarteritis Nodosa (PAN): Results of a Worldwide Collaboration Study

9:00AM-11:00AM: Abstract Number: 1690

The Long-term Outcome of Patients with Arthritis of Behçet’s Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].